Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BTaiRx, Inc. 〉CVM-1118

CVM-1118

CVM-1118

CVM-1118 is a small molecule NCE with unique ability to inhibit vasculogenic mimicry (VM).

Request for Collaboration
Overview
CVM-1118 is a small molecule NCE (new chemical entity). It has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM). CVM-1118 is currently being developed into a next generation oral anti-cancer drug. CVM-1118 has great potential showing inhibitory effect towards breast, ovarian, colon, and liver cancer in animal models. Extensive global patent coverage will allow CVM-1118 to be out-licensed to global pharmaceutical companies after phase II clinical trial for further development and marketing.
Application
Oncology
Collaboration Options
CVM-1118 is currently under Phase I clinical trials in both the US and Taiwan. We wish to seek licensing or co-development opportunities after the completion of Phase II trials.
People who like this also like
  • PHN014 (Acute ischemia stroke)PHN014 (Acute ischemia stroke)
  • PEP503 (A Radio-enhancer)PEP503 (A Radio-enhancer)
  • PHN031 (Osteoporosis prevention)PHN031 (Osteoporosis prevention)
  • Methylation-Specific-PCR (MSP)Methylation-Specific-PCR (MSP)
  • Applying next generation sequencing in preimplantation genetic screeningApplying next generation sequencing in preimplantation genetic screening
  • Platform_Polymeric MicellePlatform_Polymeric Micelle
  • Medical Image Processing Apparatus and Breast Image Processing Method ThereofMedical Image Processing Apparatus and Breast Image Processing Method Thereof
  • PipelinePipeline
  • SNP-810 (OTC)SNP-810 (OTC)
  • ELISA (FMD NSP Ab test)ELISA (FMD NSP Ab test)